1. Home
  2. FOLD vs WEN Comparison

FOLD vs WEN Comparison

Compare FOLD & WEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FOLD
  • WEN
  • Stock Information
  • Founded
  • FOLD 2002
  • WEN 1969
  • Country
  • FOLD United States
  • WEN United States
  • Employees
  • FOLD N/A
  • WEN N/A
  • Industry
  • FOLD Biotechnology: Pharmaceutical Preparations
  • WEN Restaurants
  • Sector
  • FOLD Health Care
  • WEN Consumer Discretionary
  • Exchange
  • FOLD Nasdaq
  • WEN Nasdaq
  • Market Cap
  • FOLD 2.9B
  • WEN 3.1B
  • IPO Year
  • FOLD 2007
  • WEN N/A
  • Fundamental
  • Price
  • FOLD $6.08
  • WEN $12.12
  • Analyst Decision
  • FOLD Buy
  • WEN Hold
  • Analyst Count
  • FOLD 10
  • WEN 18
  • Target Price
  • FOLD $16.22
  • WEN $16.69
  • AVG Volume (30 Days)
  • FOLD 4.6M
  • WEN 5.2M
  • Earning Date
  • FOLD 05-01-2025
  • WEN 05-02-2025
  • Dividend Yield
  • FOLD N/A
  • WEN 7.34%
  • EPS Growth
  • FOLD N/A
  • WEN N/A
  • EPS
  • FOLD N/A
  • WEN 0.94
  • Revenue
  • FOLD $543,141,000.00
  • WEN $2,235,211,000.00
  • Revenue This Year
  • FOLD $21.87
  • WEN $1.05
  • Revenue Next Year
  • FOLD $22.19
  • WEN $4.27
  • P/E Ratio
  • FOLD N/A
  • WEN $12.88
  • Revenue Growth
  • FOLD 28.25
  • WEN 2.18
  • 52 Week Low
  • FOLD $6.20
  • WEN $11.70
  • 52 Week High
  • FOLD $12.65
  • WEN $20.60
  • Technical
  • Relative Strength Index (RSI)
  • FOLD 29.58
  • WEN 35.21
  • Support Level
  • FOLD $6.63
  • WEN $11.70
  • Resistance Level
  • FOLD $7.71
  • WEN $13.06
  • Average True Range (ATR)
  • FOLD 0.30
  • WEN 0.36
  • MACD
  • FOLD -0.05
  • WEN 0.00
  • Stochastic Oscillator
  • FOLD 13.76
  • WEN 30.88

About FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

About WEN Wendy's Company (The)

The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $12.3 billion in 2023, narrowly edging Burger King ($11.5 billion) and clocking in well behind wide-moat McDonald's ($53.1 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spanned almost 7,157 total stores in 30 countries as of year-end 2023. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.

Share on Social Networks: